Stiefel Laboratories Announces Licensing Agreement

CORAL GABLES, Fla., Aug. 22 /PRNewswire/ -- Stiefel Laboratories, Inc., has announced that it has reached an exclusive worldwide licensing agreement with Italian companies, The Epitech Group s.r.l. and Innovet Italia s.r.l. The agreement grants Stiefel Laboratories, Inc., production and marketing rights for pharmaceutical and cosmetic products based on the proprietary molecule N-acyl-amides (ALIAmides) in the field of human dermatology. Epitech and Innovet developed and own the international patent portfolio for the molecule. Stiefel Laboratories markets a variety of products around the world using this important patented technology.

Viviana Amzel of Nath & Associates, San Diego, California, and Benedetto Costantino of Studio Legale Costantino, Padova, Italy, assisted the parties in the transaction.

About Stiefel Laboratories, Inc.

Founded in 1847, Stiefel Laboratories is the world's largest independent pharmaceutical company specializing in dermatology. Its wholly-owned global network is comprised of more than 30 subsidiaries, including manufacturing plants in six countries, Research and Development facilities on three continents and products marketed in 100 countries around the world.

Stiefel Laboratories supplements its R&D efforts by aggressively seeking acquisitions of dermatological product lines and companies around the world. To learn more about Stiefel Laboratories, Inc., visit http://www.stiefel.com.

Source: Stiefel Laboratories, Inc.